The CNS as a target for peptides and peptide-based drugs
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Peptides hold great potential as CNS drugs, but their delivery to the CNS is problematic. However, actual roadblocks to peptide delivery are different from those often perceived. Many peptides cross the blood-brain barrier by saturable and non-saturable mechanisms, and accumulate in brain in amounts sufficient to produce physiological effects. Peripheral factors (e.g., short half-life in blood) can be dominant factors limiting therapeutic use. Production of therapeutics that are enzymatically resistant and have long circulation times, even when the blood-brain barrier penetration is low, can result in substances with significant CNS accumulation. Surprisingly low amounts of peptide in brain can result in CNS effects, and so the dose needed for brain delivery is generally much smaller than for peripheral tissues. Brain-to-blood transporters can greatly limit CNS accumulation of a potential therapeutic. Finally, intranasal and intrathecal routes may be especially useful for substances that are rapidly degraded in blood or are large and hydrophobic, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationLipid solubility and drug penetration of the blood brain barrier
Oldendorf, W. H. (1974) · Experimental Biology and Medicine · doi:10.3181/00379727-147-38444 · Cited by 373
Cited by
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
“…(AVP) (Zlokovic et al., 1990), enkephalins (Zlokovic et al., 1987, 1989), tyrosine melanocyte-stimulating inhibitory factor 1 (TyrMIF-1), delta-sleep inducing peptide (DSIP), luteinizing-hormone releasing hormone (LHRH), and some cytokines and chemokines (Zlokovic, 1995; Banks, 2006).”
Redzic, Z. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-3 · Cited by 418
Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models
Zhang, H., Wu, C., Chen, Q., Chen, X., Xu, Z., Wu, J., & Cai, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061477 · Cited by 224
“The rationale for this possibility includes that, the blood-brain barrier (BBB) does not completely block the passage of OXT [22- 27], and more importantly, OXT when peripherally administrated can lead to activation of hypothalamic OXT neurons to induce central OXT release [15].”
InfluentialIntranasal administration of oxytocin: behavioral and clinical effects, a review
Veening, J. G., & Olivier, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.012 · Cited by 169
“For the present purpose, a short survey will suffice since numerous reviews have been considering specific aspects of IN-administration over the last few years (Banks, 2006; Bos et al., 2012; Carnes and Robinson, 2008; Charlton et al., 2008; Dale et al., 2002; Dhuria et al., 2009a, 2010; Domes et al., 2010; Graff and…”
Background
Metadata
- Authors
- Banks, W. A.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2006-10-31
- Volume
- 3
- Issue
- 6
- Pages
- 707-712
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2129205827
- Cited by
- 35
- References
- 2
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The CNS as a target for peptides and peptide-based drugs. https://app.cochat.ai/papers/10.1517/17425247.3.6.707
- The paper
- Banks, W. A. (2006). The CNS as a target for peptides and peptide-based drugs. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.3.6.707
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.